Decibel Therapeutics to Present at the Barclays Gene Editing & Gene Therapy Summit

Rhea-AI Summary

BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX) announced its participation in the Barclays Gene Editing & Gene Therapy Summit on November 15, 2021. CEO Laurence Reid, Ph.D., will engage in a fireside chat at 3:30 pm ET and a panel discussion at 4:45 pm ET focused on regulatory challenges. A live webcast of the chat will be accessible on the company’s website, with an archived replay available for 90 days post-event. Decibel Therapeutics is dedicated to developing transformative treatments for hearing and balance disorders.

BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced its participation in the fifth annual Barclays Gene Editing & Gene Therapy Summit on Monday, November 15, 2021. Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in a fireside chat at 3:30 pm ET and in a panel discussion titled “Addressing Development Challenges and the Regulatory Hurdles” at 4:45 pm ET.

A live webcast of the fireside chat may be accessed by visiting the Investors section of the Decibel Therapeutics website at https://ir.decibeltx.com. An archived replay of the webcast will be available on the Company’s website for approximately 90 days following the fireside chat.

About Decibel Therapeutics

Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel’s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of creating a world of connection for people with hearing and balance disorders. For more information about Decibel Therapeutics, please visit www.decibeltx.com or follow us on Twitter.

Investor Contact:
Julie Seidel
Stern Investor Relations, Inc.
julie.seidel@sternir.com
212-362-1200

Media Contact:
Chris Railey
Ten Bridge Communications
Chris@tenbridgecommunications.com
617-834-0936

 

FAQ

What is the significance of Decibel Therapeutics' participation in the Barclays Summit?

Decibel Therapeutics will discuss key challenges in gene therapy and share insights on their innovative treatments for hearing and balance disorders.

When will Decibel Therapeutics' CEO speak at the Barclays Summit?

Laurence Reid, CEO of Decibel Therapeutics, will speak on November 15, 2021, at 3:30 pm ET.

What topics will be covered during Decibel Therapeutics' panel discussion at the summit?

The panel discussion will address development challenges and regulatory hurdles in gene therapy.

How can I access the live webcast of Decibel Therapeutics' fireside chat?

The live webcast can be accessed through the Investors section of Decibel Therapeutics' website.

What is the main focus of Decibel Therapeutics as a biotechnology company?

Decibel Therapeutics focuses on developing transformative treatments to restore and improve hearing and balance, targeting unmet medical needs.